Ranbaxy Plans to Re-Launch Skincare Brand Sotret in U.S.

India’s largest drug maker Ranbaxy Laboratories plans to re-launch its former flagship skincare brand Sotret (isotretinoin) in the U.S., that has been banned for almost four years, through a marketing partnership with a Canadian firm Cipher Pharmaceuticals.
The Economic Times